Literature DB >> 2252366

Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection.

B J Brew1, R B Bhalla, M Paul, H Gallardo, J C McArthur, M K Schwartz, R W Price.   

Abstract

We evaluated cerebrospinal fluid (CSF) concentrations of neopterin, a putative marker of activated macrophages, in 97 subjects infected with human immunodeficiency virus type 1 who had a spectrum of neurological complications. The highest CSF neopterin concentrations occurred in those with neurological opportunistic infections, primary central nervous systems lymphoma, and acquired immunodeficiency syndrome (AIDS) dementia complex. In general, the CSF concentration of neopterin was independent of CSF cell count and blood-brain barrier disruption to albumin. In the patients with AIDS dementia complex, CSF neopterin concentrations correlated with severity of disease and decreased in conjunction with clinical improvement following treatment with zidovudine. These results suggest that CSF neopterin, although not disease-specific, may be useful as a surrogate marker for the presence of AIDS dementia complex and its response to antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252366     DOI: 10.1002/ana.410280413

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

Review 1.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

2.  Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.

Authors:  Josué Pérez-Santiago; Rachel D Schrier; Michelli F de Oliveira; Sara Gianella; Susanna R Var; Tyler R C Day; Miguel Ramirez-Gaona; Jesse D Suben; Ben Murrell; Marta Massanella; Mariana Cherner; Davey M Smith; Ronald J Ellis; Scott L Letendre; Sanjay R Mehta
Journal:  J Neurovirol       Date:  2015-10-01       Impact factor: 2.643

3.  Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment.

Authors:  L Hagberg; G Norkrans; M Andersson; H Wachter; D Fuchs
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

4.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 5.  A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV.

Authors:  Norman J Haughey; Xiaomao Zhu; Veera Venkata Ratnam Bandaru
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-08       Impact factor: 4.147

6.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens.

Authors:  C Jassoy; T Harrer; T Rosenthal; B A Navia; J Worth; R P Johnson; B D Walker
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Authors:  Hans-Jürgen von Giesen; Ortwin Adams; Hubertus Köller; Gabriele Arendt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

8.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

9.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 10.  Review of antiretroviral therapy in the prevention of HIV-related AIDS dementia complex (ADC).

Authors:  P Portegies
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.